Affiliation:
1. From the Departments of Obstetrics and Gynecology and Surgical Pathology, Ospedale San Gerardo di Monza, University of Milano Bicocca, Milan, Italy.
Abstract
PURPOSE: Borderline tumors account for 10% to 20% of epithelial ovarian tumors, and their prognosis is outstanding; nevertheless, a mortality of up to 20% has been reported, particularly in earlier reports. There is a lack of information about the actual mortality and the rate of progression into invasive carcinoma in large and prospectively accrued populations. PATIENTS AND METHODS: All women with borderline ovarian tumors undergoing primary surgery in our department or referred within 3 months from surgery performed elsewhere from 1982 to 1997 were prospectively accrued and observed. RESULTS: We studied 339 women (83.4% stage I, 7.9% stage II, and 8.5% stage III). The median age at diagnosis was 39 years. A total of 150 women underwent radical surgery, and 189 underwent fertility-sparing surgery. After surgery, 13 women had macroscopic residual disease. With a median follow-up of 70 months, 317 women are alive with no clinical disease (eight with documented subclinical persistence of implants), three are alive with clinical disease, two died of disease, 10 died of other reasons, and seven women have been lost to follow-up. The recurrence of disease was higher after fertility-sparing surgery (35 of 189 cases) than after radical surgery (seven of 150 cases); nevertheless, all but one woman with recurrence of borderline tumor or progression to carcinoma after conservative surgery were salvaged. We observed seven progressions (2.0%) into invasive carcinoma, five in serous tumors (2.4%), and two in mucinous tumors (1.6%). The disease-free survival is 99.6% in stage I patients, 95.8% in stage II, and 89% in stage III. CONCLUSION: The survival of patients with borderline tumors is higher than previously described in some retrospective studies. Conservative surgery is safe and may be proposed to several patients with early and disseminated disease after thorough discussion of all therapeutic options. Progression to carcinoma is approximately 2% and may be observed in both mucinous and serous tumors.
Publisher
American Society of Clinical Oncology (ASCO)
Reference25 articles.
1. Taylor HC: Malignant and semimalignant tumors of the ovary. Surg Gynaecol Obstet 48: 204,1929-230,
2. Ovarian epithelial tumors of borderline malignancy: A clinical and pathologic study of 109 cases
3. Elchalal U, Dgani R, Piura B, et al: Current concepts in management of epithelial ovarian tumors of low malignant potential. Obstet Gynecol Surv 50: 62,1994-70,
4. Julian CG, Woodruff JD: The biologic behavior of low grade papillary serous carcinoma of the ovary. Obstet Gynecol 40: 860,1972-867,
5. Aure JC, Hoeg K, Kolstad P: Clinical and histologic studies of ovarian cancer. Obstet Gynecol 37: 1,1971-9,
Cited by
354 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献